MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Abstract:: OBJECTIVE: To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival. PATIENTS AND METHODS: We conducted centralized immunohistochemical staining, semi-quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December 31, 2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than 12,000 person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4, and staining intensity was classified using a 2-tiered system for each marker (weak vs strong). RESULTS: Expression of MyD88 and TLR4 was similar in all histotypes except clear cell ovarian cancer, which showed reduced expression compared with other histotypes (P

Authors:: MS Block, RA Vierkant, PF Rambau, SJ Winham, P Wagner, N Traficante, A Tołoczko, DG Tiezzi, FA Taran, P Sinn, W Sieh, R Sharma, JH Rothstein, T Ramón Y Cajal, L Paz-Ares, O Oszurek, S Orsulic, RB Ness, G Nelson, F Modugno, J Menkiszak, V McGuire, BM McCauley, M Mack, J Lubiński, TA Longacre, Z Li, J Lester, CJ Kennedy, KR Kalli, AY Jung, SE Johnatty, M Jimenez-Linan, A Jensen, MP Intermaggio, J Hung, E Herpel, BY Hernandez, AD Hartkopf, PR Harnett, P Ghatage, JM García-Bueno, B Gao, S Fereday, U Eilber, RP Edwards, CB de Sousa, JM de Andrade, A Chudecka-Głaz, G Chenevix-Trench, A Cazorla, SY Brucker, Australian Ovarian Cancer Study Group, J Alsop, AS Whittemore, H Steed, A Staebler, KB Moysich, U Menon, JM Koziak, S Kommoss, SK Kjaer, LE Kelemen, BY Karlan, DG Huntsman, E Høgdall, J Gronwald, MT Goodman, B Gilks, MJ García, PA Fasching, A de Fazio, S Deen, J Chang-Claude, FJ Candido Dos Reis, IG Campbell, JD Brenton, DD Bowtell, J Benítez, PDP Pharoah, M Köbel, SJ Ramus, EL Goode

Themes